TABLE 2.
Baseline characteristics of the University of Michigan cohort
| Total | No PH | PH | p-value | |
|---|---|---|---|---|
| Subjects | 268 | 124 | 144 | |
| Age years | 60.6±11.7 | 59.6±12.1 | 61.5±11.3 | 0.323 |
| Female | 228 (85.07) | 106 (85.48) | 122 (84.72) | 0.862 |
| Race | ||||
| Caucasian | 212 (79.10) | 98 (79.03) | 114 (79.17) | 0.112 |
| African-American | 38 (14.18) | 14 (11.29) | 24 (16.67) | |
| Other | 18 (6.72) | 12 (9.68) | 6 (4.17) | |
| Type of SSc | ||||
| Limited cutaneous SSc | 154 (57.46) | 77 (62.10) | 77 (53.47) | 0.174 |
| Diffuse cutaneous SSc | 94 (35.07) | 42 (33.87) | 52 (36.1 1) | |
| Sine scleroderma | 9 (3.36) | 3 (2.42) | 6 (4.17) | |
| MCTD | 11 (4.10) | 2 (1.61) | 9 (6.25) | |
| Disease duration# years | 9.8±9.1 | 10.3±8.8 | 9.4±9.5 | 0.152 |
| Autoantibodies | ||||
| Antinuclear antibody (n=236) | 213 (90.25) | 99 (89.19) | 114 (91.20) | 0.603 |
| Anticentromere (n=181) | 44 (24.31) | 18 (21.43) | 26 (26.80) | 0.401 |
| Anti-RNA polymerase 3 (n=84) | 17 (20.24) | 8 (19.51) | 9 (20.93) | 0.872 |
| Anti-Scl-70 (n=225) | 32 (14.22) | 21 (20.79) | 11 (8.87) | 0.011 |
| Anti-U1 ribonucleoprotein (n=218) | 32 (14.68) | 12 (11.65) | 20 (17.39) | 0.232 |
| HRCT showing ILD (n=226) | 164 (72.57) | 80 (77.67) | 84 (68.29) | 0.116 |
| Pulmonary function tests | ||||
| FVC % pred | 76.4±20.3 | 80.2±18.7 | 73.1±21.0 | 0.004 |
| Dlco % pred (n=253) | 50.0±18.5 | 57.1±17.2 | 43.8±17.4 | <0.0001 |
| Right heart catheterisation | ||||
| mPAP mmHg | 30.6±11.9 | 22.0±5.0 | 37.9±11.2 | <0.0001 |
| PAWP mmHg | 12.6±4.7 | 11.1±3.0 | 13.9±5.4 | <0.0001 |
| TPG mmHg | 18.0±11.5 | 10.9±4.0 | 24.0±12.3 | <0.0001 |
| Cardiac output L·min−1 | 5.5±1.6 | 5.9±1.5 | 5.0±1.5 | <0.0001 |
| PVR WU | 3.9±3.7 | 1.9±0.6 | 5.6±4.3 | <0.0001 |
Data are presented as n, mean±sd or n (%), unless otherwise stated. SSc: systemic sclerosis; MCTD: mixed connective tissue disease; HRCT: high-resolution computed tomography; ILD: interstitial lung disease; FVC: forced vital capacity; Dlco: diffusing capacity of the lung for carbon monoxide; mPAP: mean pulmonary arterial pressure; PAWP: pulmonary arterial wedge pressure; TPG: transpulmonary gradient; PVR: pulmonary vascular resistance; WU: Wood Units.
#:
disease duration calculated from date of first non-Raynaud’s symptom to date of RHC.